There are currently 1308 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
NCT05928936
Recruiting
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
09/10/2024
Locations: Emory Clinic, Atlanta, Georgia
Conditions: Chronic Kidney Disease
Register for Updates
Role of Early Motor Experience in Infants With Down Syndrome
NCT05144373
Recruiting
Infants with Down syndrome show significant delays and weaknesses in motor, cognitive, and language development compared to typically developing infants. This project aims to examine the developmental cascade effects of specific gross and fine motor experience on motor, cognitive and language development in infants with Down syndrome. We propose that both gross and fine motor experience will facilitate cognitive and language development in infants with Down syndrome, and particularly, fine motor... Read More
Gender:
ALL
Ages:
Between 7 months and 24 months
Trial Updated:
09/09/2024
Locations: Biomechanics lab, Atlanta, Georgia
Conditions: Down Syndrome
Register for Updates
Improving Sleep and Cognition in Alzheimer's Disease
NCT05200208
Recruiting
Cognitive disorders include such things as memory disorders, mild cognitive impairment, and Alzheimer's disease (AD). The purpose of the study is to learn more about whether a dietary citicoline supplement will improve sleep and cognition. Sleep disturbances currently afflict approximately 25-44% of those with AD, resulting in decreased quality of life for those with AD and their caregivers and are a major driver of institutionalization. Previous studies have tested this dietary supplement in A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Emory University School of Nursing, Atlanta, Georgia +1 locations
Conditions: Alzheimer Disease
Register for Updates
Gemcitabine, Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326
Recruiting
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy has been shown to improve overall survival compared to patients receiving surgery first. Gemcitabine is a chemot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Register for Updates
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
NCT04416568
Recruiting
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Gender:
ALL
Ages:
Between 6 months and 40 years
Trial Updated:
09/09/2024
Locations: Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia +1 locations
Conditions: Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Register for Updates
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
NCT04776395
Recruiting
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their CART and Have Dual- or Triple-class Antiretroviral Resistance
NCT04648280
Recruiting
In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and swallowability of formulation among the pediatric population. The dose selection of FTR for children and adolescents ≥20kg utilized a population pharmacokinetic (POP PK) model-based approach to achieve similar adult TMR exposures following FTR 600mg BID administration with combination therapy that was... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
09/04/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: HIV Infections With Multi Drug Resistant Virus
Register for Updates
Neuroblastoma Biology Study
NCT01587300
Recruiting
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More
Gender:
ALL
Ages:
Between 31 days and 99 years
Trial Updated:
09/01/2024
Locations: AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia
Conditions: Neuroblastoma
Register for Updates
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Emory University - Winship Cancer Institute, Atlanta, Georgia
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Register for Updates
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Acute Ischemic Stroke
Register for Updates
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
NCT06295458
Recruiting
This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG). Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public healt... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
08/27/2024
Locations: Emory Movement Disorders Center, Atlanta, Georgia
Conditions: Gait Disorders, Neurologic, Parkinson Disease
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates